Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL4298086

POZELIMAB
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
No structure available

Basic Information

ChEMBL ID CHEMBL4298086
Name POZELIMAB
Phase Approved
Structure Type SEQ
Therapeutic ✓ Yes

Known Names

Pozelimab Pozelimab-bbfg REGN-3918 Regn3918 Veopoz
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
5
Known Names
4
Indications
1
Mechanisms

Drug Information

Molecule Type Antibody
First Approval 2023
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Parenteral

Flags

Black Box Warning First in Class
USAN Stem -mab
USAN Year 2018

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Complement C5 inhibitor INHIBITOR Complement C5

Indications

Protein-Losing Enteropathies Hemoglobinuria Myasthenia Gravis Hemoglobinuria, Paroxysmal

ATC Classification

L04AJ11
pozelimab
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: IMMUNOSUPPRESSANTS

Drug Warnings

Black Box Warning
infectious disease
Country: United States
Black Box Warning
neurotoxicity
Country: United States

Data from ChEMBL 36 via Core Engine